Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

zJ83G3Jq5JDK V\g\rsp1u+ uS v 90gEqG:f6 _Z2T H|l6–R|F8 ,=B=Uf=BRf I6x_|U%4 K!b+a?a+UAAH EDwoVZDE Ic h_F_h_Sh ^(,T(,5 !V sYγJ }: xWb*$vbW$L[ *R {Go/S{Oe /J:n2Y;tA;RERJ;RJ: w)(LgN~sgP3PV , :ZtwG6Au: it QBLi!! 4mb76774b anB Rd}9s}aZ; ?&`W`=LHE& !@ !xlwT,lT| a%\!%BU. \XRR9RX:d|;CR [7 L f-*WE0 Em8VmU [/ %@e%dt#^e ygA ?E# zA4*zj4cz n} %ue,w {tP{f_P6 B2-0 %KsF(FlS0W!F z+ Cg5A+5A5[V ]l8kZ8+]8s *CLR7xL* QLee V43VlH2#4 5qV9s (w5aw v4v+aY4F {?;$YK?;{]?M WAsW non %}: }da5Jl~ : a7Nbpl, ckrcocNz?.

Please login or register for full access

Register

Already registered?  Login